Background
Methods
Results
All patients | ≤8 years | > 8 years | p-value | |
---|---|---|---|---|
Number of patients | 49 | 17 | 32 | |
Number of eyes | 80 | 27 | 53 | |
Number of males (%) | 22 (45) | 6 (35.3) | 16 (50.0) | 0.37 |
Mean age at presentation, years (SDa) | 11.4 (3.6) | 8.5 (3.7) | 12.9 (2.6) | < 0.0001 |
Mean age at beginning of symptoms, years (SD) | 9.15 (4.2) | 4.3 (2.4) | 11.9 (1.9) | < 0.0001 |
Mean time of uveitis before presentation, months (SD) | 23.74 (32.3) | 45.1 (40.8) | 11.6 (17.7) | 0.004 |
Mean follow up, months (SD) | 13.2 (15.1) | 15.8 (17.9) | 11.9 (13.6) | 0.44 |
Mean number of uveitis episodes (SD) | 12.6 (0.4) | 15.4 (18.3) | 11.2 (13) | 0.37 |
Bilateral, n (%) | 31 (63.3) | 10 (58.8) | 21 (65.6) | 0.63 |
Location, n (%) | ||||
Anterior | 20 (40.8) | 10 (58.8) | 10 (30.3) | 0.06 |
Panuveitis | 13 (26.5) | 3 (17.6) | 10 (31.2) | 0.31 |
Posterior | 10 (20.4) | 2 (11.8) | 8 (25.0) | 0.27 |
Intermediate | 6 (12.3) | 2 (11.8) | 4 (12.1) | 1.00 |
Chronicity, n (%) | ||||
Acute | 12 (24.5) | 2 (11.8) | 10 (30.3) | 0.13 |
Chronic | 30 (61.2) | 11 (64.7) | 19 (59.4) | 0.71 |
Recurrent | 7 (14.3) | 4 (23.5) | 3 (9.1) | 0.18 |
Etiology | All patients n = 49 | ≤8 years n = 17 | > 8 years n = 32 | p-value |
---|---|---|---|---|
Idiopathic | 25 (51.0) | 10 (58.8) | 15 (46.9) | 0.42 |
Autoimmune | 14 (28.6) | 4 (23.5) | 10 (31.2) | 0.57 |
JIAa | 6 (12.2) | 3 (17.6) | 3 (9.4) | 0.17 |
Behcet | 3 (6.1) | 0 (0) | 3 (9.4) | |
Sarcoidosis | 1 (2.0) | 0 (0) | 1 (3.1) | |
VKHb | 1 (2.0) | 0 (0) | 1 (3.1) | |
IBDc | 0 (0) | 1 (5.9) | 1 (3.1) | |
Takayasu | 1 (2.0) | 0 (0) | 1 (3.1) | |
TINUd | 1 (2.0) | 0 (0) | 1 (3.1) | |
Infectious | 10 (20.4) | 3 (17.6) | 7 (21.9) | 0.73 |
Toxoplasmosis | 5 (10.2) | 2 (11.8) | 3 (9.4) | |
HSVe | 2 (4.1) | 1 (5.9) | 1 (3.1) | |
PORNf | 1 (2.0) | 0 (0) | 1 (3.1) | |
CMVg | 1 (2.0) | 0 (0) | 1 (3.1) | |
TBh | 1 (2.0) | 0 (0) | 1 (3.1) |
Complications | All eyes n = 80 | ≤8 years n = 27 | > 8 years n = 53 | p-value |
---|---|---|---|---|
Cataract | 20 (25.0) | 8 (29.6) | 12 (22.6) | 0.58 |
Ocular hypertension | 15 (18.75) | 7 (26.0) | 8 (15.0) | 0.15 |
Glaucoma | 3 (3.75) | 0 (0) | 3 (5.7) | < 0.001 |
Amblyopia | 5 (6.3) | 5 (18.5) | 0 (0) | < 0.003 |
CMEa | 8 (10.0) | 4 (14.8) | 4 (7.5) | 0.43 |
Posterior synechiae | 26 (32.5) | 15 (55.6) | 11 (20.7) | 0.002 |
Band keratopathy | 10 (12.5) | 7 (25.9) | 3 (5.7) | 0.03 |
Vasculitis | 18 (22.5) | 0 (0) | 18 (34.0) | < 0.001 |
Papillitis | 20 (25.0) | 4 (14.8) | 16 (30.2) | 0.17 |
Vitreal haze | 30 (37.5) | 6 (22.2) | 24 (45.3) | 0.04 |
All eyes | ≤8 years | > 8 years | p-value | |
---|---|---|---|---|
At initial visit | n = 76 | n = 25 | n = 51 | |
VAa ≤ 20/50 | 32 (42.1) | 13 (52.0) | 19 (37.3) | 0.22 |
VA ≤ 20/200 | 14 (18.4) | 7 (28.0) | 7 (13.7) | 0.13 |
At 6 months | n = 54 | n = 18 | n = 36 | |
VA ≤ 20/50 | 12 (22.2) | 6 (33.3) | 6 (16.6) | 0.18 |
VA ≤ 20/200 | 5 (9.3) | 2 (11.1) | 3 (8.3) | 1.00 |
Improvement≥2 lines | 16 (29.6) | 9 (50.0) | 7 (19.4) | 0.02 |
Worsening≥2 lines | 4 (7.4) | 1 (5.6) | 3 (8.3) | 1.00 |
At 1 year | n = 49 | n = 18 | n = 31 | |
VA ≤ 20/50 | 18 (36.7) | 7 (38.9) | 11 (35.5) | 0.81 |
VA ≤ 20/200 | 7 (14.3) | 2 (11.1) | 5 (16.1) | 0.63 |
Improvement≥2 lines | 18 (36.7) | 10 (55.6) | 8 (25.8) | 0.037 |
Worsening≥2 lines | 11 (22.4) | 2 (11.1) | 9 (29) | 0.19 |
At last visit | ||||
VA ≤ 20/50 | 24 (31.6) | 9 (36.0) | 15 (29.4) | 0.56 |
VA ≤ 20/200 | 10 (13.2) | 3 (12.0) | 7 (13.7) | 0.83 |
Improvement≥2 lines | 17 (22.3) | 9 (36.0) | 8 (15.7) | 0.076 |
Worsening≥2 lines | 7 (9.2) | 1 (4.0) | 6 (11.8) | 0.41 |
Discussion
Etiology (%) | Anatomical classification (%) | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Country | Sample size | Idiopathic | Auto-immune | Most common autoimmune etiology | Infectious | Most common organism | Anterior | Intermediate | Posterior | Panuveitis |
Italy [20] (2009) | 257 | 12.8 | 55.4 | JIA | 31 | Toxoplasma | 47.8 | 19.4 | 24.9 | 7.8 |
Turkey [30] (2012) | 121 | 16.5 | 62 | Pars planitis | 21.5 | Toxoplasma | 31.4 | 25.6 | 24.8 | 18.2 |
Tunisia [31] (2005) | 64 | 50 | 25 | Behcet’s and JIA | 25 | Toxoplasma | 31.25 | 31.25 | 20.3 | 17.2 |
Egypt [32] (2017) | 413 | 28.5 | 35 | JIA | 36 | presumed parasitic anterior uveitis | 27.1 | 30 | 18.6 | 24.2 |
KSA [33] (2007) | 163 | 5 | 83 | VKH | 12 | Toxoplasma | 42 | 20 | 7 | 31 |
Lebanon (current study) | 50 | 51 | 28.6 | JIA | 20.4 | Toxoplasma | 40.8 | 12.3 | 20.4 | 26.5 |